Edward M. Kaye MD - 01 Dec 2025 Form 4 Insider Report for Stoke Therapeutics, Inc. (STOK)

Role: Director
Signature: /s/ Jonathan Allan, Attorney-in-Fact
Issuer symbol: STOK
Transactions as of: 01 Dec 2025
Net transactions value: -$64,541
Form type: 4
Filing time: 03 Dec 2025, 20:22:08 UTC
Previous filing: 12 Nov 2025
Next filing: 05 Dec 2025
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Kaye Edward M. MD	Director	C/O STOKE THERAPEUTICS, INC., 45 WIGGINS AVENUE, BEDFORD	/s/ Jonathan Allan, Attorney-in-Fact	03 Dec 2025	0001522780

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	STOK	Common Stock	Options Exercise	$0	+4,317	+8.8%	$0.000000	53,441	01 Dec 2024	Direct
transaction	STOK	Common Stock	Sale	$19,540	-661	-1.2%	$29.56	52,780	02 Dec 2025	Direct	F1, F2
transaction	STOK	Common Stock	Sale	$12,207	-405	-0.77%	$30.14	52,375	02 Dec 2025	Direct	F1, F3
transaction	STOK	Common Stock	Sale	$12,712	-419	-0.8%	$30.34	51,956	03 Dec 2025	Direct	F1, F4
transaction	STOK	Common Stock	Sale	$20,082	-651	-1.3%	$30.85	51,305	03 Dec 2025	Direct	F1, F5

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	STOK	Restricted Stock Units	Options Exercise	$0	-4,317	-100%	$0.000000	0	01 Dec 2025	Common Stock	4,317		Direct	F6, F7

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The reported transaction represents an Issuer mandated sale to satisfy tax withholding liabilities in connection with the vesting and settlement of restricted stock units.
F2	The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.93 to $29.92 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and in footnotes 3 through 5.
F3	The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.93 to $30.63 per share, inclusive.
F4	The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.81 to $30.805 per share, inclusive.
F5	The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.815 to $31.17 per share, inclusive.
F6	Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock upon settlement.
F7	21,591 restricted stock units vested on December 1, 2024 and 4,317 vest on December 1, 2025, subject to the reporting person's continued service to the Issuer on each such date.